{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282679626766848.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.2177/jsci.31.375"}},{"identifier":{"@type":"URI","@value":"http://www.jstage.jst.go.jp/article/jsci/31/5/31_5_375/_pdf"}},{"identifier":{"@type":"PMID","@value":"18974621"}},{"identifier":{"@type":"NAID","@value":"10024961409"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2009039979"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@language":"en","@value":"Cancer antigen WT1-targeting treatment for the malignancies  -Development of WT1 peptide vaccine-"},{"@language":"ja","@value":"癌抗原ＷＴ１を標的とした免疫療法　　―ＷＴ１ペプチド癌ワクチン―"}],"dcterms:alternative":[{"@language":"en","@value":"—Development of WT1 peptide vaccine—"},{"@language":"ja","@value":"—WT1ペプチド癌ワクチン—"}],"dc:language":"ja","description":[{"type":"abstract","notation":[{"@language":"en","@value":"Wilm's tumor gene <i>WT1</i>, which has an oncogenic function, is expressed in various kinds of hematological malignancies and solid cancers. WT1 antibodies at higher titers and WT1-specific cytotoxic T lymphocytes (CTLs) at higher frequencies were detected in cancer patients than in healthy donors, indicating that WT1 protein was immunogenic. Furthermore, WT1-specific immune responses are considered to be involved with Graft versus Leukemia effect in the context of hematopoietic stem cell transplantation. These findings provided us with the rationale for cancer immunotherapy targeting WT1. Clinical trials of WT1 peptide vaccination for cancer patients were started, and WT1 vaccination-driven immunological responses and clinical responses, including reduction of leukemic cells, reduction of M-protein amount in myeloma, and shrinkage of solid cancer, were observed. Further enhancement of efficacy of WT1 peptide vaccine can be expected by co-administration of WT1-specific helper peptide or anti-cancer chemotherapy agent. WT1 peptide vaccination in the setting of MRD (minimal residual disease) may prolong “progression-free survival time”, or decrease “relapse rate”.<br>"},{"@language":"ja","@value":"癌遺伝子としての機能を有する<i>WT1</i>遺伝子（Wilm's tumor gene）は多くの造血器腫瘍や固形癌で発現している．その遺伝子産物であるWT1蛋白は抗原性が高く癌免疫療法の標的としてすぐれていることを示す実験データが蓄積されつつある．つまり，癌患者の末梢血では健常人に比較してWT1抗体が高力価で，また，WT1特異的CTL (cytotoxic T lymphocyte）が高頻度で検出される．さらに，造血幹細胞移植時のGraft versus Leukemia反応にもWT1特異的免疫反応が関与している可能性が高い．これらの知見をもとに，WT1特異的CTLを誘導できるWT1ペプチドを癌ワクチンとして投与する臨床試験が開始された．その結果，WT1ペプチドワクチン投与患者において，投与されたWT1ペプチド特異的な細胞性免疫反応の誘導（WT1特異的CTL頻度の増加，ペプチド特異的DTH反応の陽性化など），および，それに基づくと考えられる臨床的反応（白血病細胞の減少，多発性骨髄腫におけるM蛋白の減少，固形腫瘍の縮小など）がみとめられた．今後，ヘルパーペプチドや化学療法との併用などにより，WT1ペプチドワクチンのさらなる効果の増強が期待できる．また，WT1ペプチドワクチンなどの免疫治療はMRD (minimal residual disease）時の再発予防に最適であると考えられる．<br>"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1420001326229232128","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"20273691"},{"@type":"NRID","@value":"1000020273691"},{"@type":"NRID","@value":"9000364938238"},{"@type":"NRID","@value":"9000405687542"},{"@type":"NRID","@value":"9000014282434"},{"@type":"NRID","@value":"9000002549716"},{"@type":"NRID","@value":"9000002256018"},{"@type":"NRID","@value":"9000253021457"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0046463"}],"foaf:name":[{"@language":"en","@value":"OKA Yoshihiro"},{"@language":"ja","@value":"岡 芳弘"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Graduate School of Medicine, Osaka University"},{"@language":"ja","@value":"大阪大学大学院医学系研究科呼吸器・免疫アレルギー内科学"}]},{"@id":"https://cir.nii.ac.jp/crid/1410853646458503552","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000014523834"}],"foaf:name":[{"@language":"en","@value":"KAWASE Ichiro"},{"@language":"ja","@value":"川瀬 一郎"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Graduate School of Medicine, Osaka University"},{"@language":"ja","@value":"大阪大学大学院医学系研究科呼吸器・免疫アレルギー内科学"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09114300"},{"@type":"EISSN","@value":"13497413"},{"@type":"NCID","@value":"AN00357971"}],"prism:publicationName":[{"@language":"en","@value":"Japanese Journal of Clinical Immunology"},{"@language":"ja","@value":"日本臨床免疫学会会誌"},{"@language":"en","@value":"Jpn. J. Clin. Immunol."},{"@language":"ja","@value":"日臨免誌"},{"@language":"en","@value":"Jpn.J.clin.Immun"}],"dc:publisher":[{"@language":"en","@value":"The Japan Society for Clinical Immunology"},{"@language":"ja","@value":"日本臨床免疫学会"}],"prism:publicationDate":"2008","prism:volume":"31","prism:number":"5","prism:startingPage":"375","prism:endingPage":"382"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"http://www.jstage.jst.go.jp/article/jsci/31/5/31_5_375/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2009039979"}],"availableAt":"2008","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=WT1","dc:title":"WT1"},{"@id":"https://cir.nii.ac.jp/all?q=cancer","dc:title":"cancer"},{"@id":"https://cir.nii.ac.jp/all?q=immunotherapy","dc:title":"immunotherapy"},{"@id":"https://cir.nii.ac.jp/all?q=vaccine","dc:title":"vaccine"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040282257454635776","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"19590894"},{"@type":"JGN","@value":"JP19590894"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19590894/"}],"notation":[{"@language":"ja","@value":"肺癌を標的とした、WT1ペプチド癌ワクチン療法の開発"},{"@language":"en","@value":"Development of WT1 peptide cancer vaccine targeting lung cancer"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360292619970609536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Myeloma Cells Are Highly Sensitive to the Granule Exocytosis Pathway Mediated by WT1-Specific Cytotoxic T Lymphocytes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620897957888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574093522809344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene ( WT1  ) product"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095502263168","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044529089280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045908306816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519394781696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519639826048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Humoral immune responses against Wilms tumor gene WT1product in patients with hematopoietic malignancies"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995132439040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996070685824","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Subject Index"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981471213792896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946137760896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"<b>\n                     <i>In vitro</i>\n                  </b> Stimulation with WT1 Peptide-Loaded Epstein-Barr Virus-Positive B Cells Elicits High Frequencies of WT1 Peptide-Specific T Cells with <b>\n                     <i>In vitro</i>\n                  </b> and <b>\n                     <i>In vivo</i>\n                  </b> Tumoricidal Activity"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946312150784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946376151936","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894550415872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cancer Immunotherapy Targeting Wilms’ Tumor Gene WT1 Product"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844647156864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"WT1 peptide vaccine for the treatment of cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845980516864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Translational Mini-Review Series on Vaccines:&#x2028;Peptide vaccines for myeloid leukaemias"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318246251648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Induction of\n            <i>WT1</i>\n            (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318859395072","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320187576704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme"}]},{"@id":"https://cir.nii.ac.jp/crid/1520291855982502144","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma"},{"@language":"ja-Kana","@value":"WT1 Wilms tumor 1 peptide immunotherapy for renal cell carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291225764352768","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572700543982976","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Wilms Tumor Gene WT1 Peptide-Based Immunotherapy Induced a Minimal Response in a Patient with Advanced Therapy-Resistant Multiple Myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572700741063168","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Identification and characterization of a WT1 (Wilms tumor gene) orotein-derived HLA-DRB1^*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572700741064320","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"WT1 peptide vaccine for the treatment of cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1570854175717772672","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers"}]},{"@id":"https://cir.nii.ac.jp/crid/1570854175717774976","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Induction of WT1 (Wilm's tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression"}]},{"@id":"https://cir.nii.ac.jp/crid/1571135650694484864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Phase II clinical trial of WT1 (Wilms tumor gene) peptide vaccination for patients with recurrent glioblastoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1571980075624622848","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261550601326720","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Antilung cancer effect of WT1-specific cytotoxic T lymphocytes"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261550601328000","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261550601330432","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Leukemia-associated antigen specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261550601331584","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261550974724736","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1572543025578043008","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Translational mini-review series on vaccines : Peptide vaccines for myeloid leukemias"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824499795465728","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Wilms Tumor Gene Peptide-Based Immunotherapy for Patients with Overt Leulemia from Myelodysplastic Syndrome (MDS) or MDS with Myelofibrosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824500554748672","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824500554752384","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease : a multicentre observational trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105976559565824","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Cancer immunotherapy targeting Wilms' tumor gene WT1 product"}]},{"@id":"https://cir.nii.ac.jp/crid/1573387449131120384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"WT1 (Wilms' Tumor 1) peptide immunotherapy for renal cell carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1573387450508175872","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950400461594240","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Human cytotoxic T-lymphocyte responses specific for peptides of the wildtype Wilm's tumor gene (WT1) product"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950400461595520","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0032028397"},{"@type":"CROSSREF","@value":"10.2177/jsci.31.375"},{"@type":"CIA","@value":"10024961409"},{"@type":"KAKEN","@value":"PRODUCT-11689241"},{"@type":"OPENAIRE","@value":"doi_dedup___::3cdfce9967a6dbc463b81c871dc0d674"}]}